Recent research studies surrounding Retatrutide , specifically the high-dose formulation ZPHC ZPHC, indicate a considerable effect on body mass decrease and related chronic illnesses . Researchers anticipate that this dual agonist , influencing both GLP-1 and GIP receptors , could provide a major